Cargando…
First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases
PURPOSE: PI3Ks are potential therapeutic targets in immune-inflammatory diseases. These studies aimed to investigate the safety, tolerability and PK profile of seletalisib, a selective inhibitor of PI3Kδ in humans. METHODS: These phase I, randomised, double-blind, placebo-controlled, single-centre s...
Autores principales: | Helmer, Eric, Watling, Mark, Jones, Emma, Tytgat, Dominique, Jones, Mark, Allen, Rodger, Payne, Andrew, Koch, Annelize, Healy, Eugene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384962/ https://www.ncbi.nlm.nih.gov/pubmed/28160012 http://dx.doi.org/10.1007/s00228-017-2205-7 |
Ejemplares similares
-
Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ(9)-tetrahydrocannabinol: a pilot study
por: Peters, Erica N., et al.
Publicado: (2021) -
A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib
por: Atiq, Ferdows, et al.
Publicado: (2016) -
Population pharmacokinetics of haloperidol in terminally ill adult patients
por: Franken, L. G., et al.
Publicado: (2017) -
Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients
por: Abdulla, Alan, et al.
Publicado: (2020) -
Converting cyclosporine A from intravenous to oral administration in hematopoietic stem cell transplant recipients and the role of azole antifungals
por: Atiq, Ferdows, et al.
Publicado: (2018)